Aerion Bioscience

The Urgent Need for Affordable Early Lung Cancer Screening Programs A new study led by scientists at the University of Illinois at Urbana-Champaign has identified a potential driver of aggressive lung cancer tumors in patients living in high-violence neighborhoods. This groundbreaking research reveals a critical link between chronic #stress and #lungcancer progression, emphasizing the urgent need for affordable early lung #cancer screening programs. The study, detailed in the journal Cancer Research Communications, was designed to explore why Black men have a higher incidence of lung cancer than white men, despite smoking less and starting later in life. Researchers found that chronic stress, indicated by higher levels of hair cortisol, is significantly elevated in Black men living in violent neighborhoods. This chronic stress appears to influence lung cancer prognosis through complex biological mechanisms involving glucocorticoids, a group of steroid hormones. Glucocorticoids, such as cortisol, bind to receptors that regulate gene activity. These receptors play crucial roles in lung tissue development, metabolism, inflammation, and immune function. The study discovered that patterns of gene expression and glucocorticoid receptor binding differ significantly between cancerous and healthy lung tissues, as well as between individuals living in high- and low-violence areas. Notably, within tumor tissues, those living in high-crime zip codes exhibited lower glucocorticoid receptor binding and lower levels of GR-regulated genes, which are associated with worse lung cancer outcomes. These findings underscore the profound impact of environmental stress on lung cancer progression. The research clearly suggests that stress responses in high-violence areas are dysregulated, directly affecting cellular physiology and cancer progression. Given these insights, there is a compelling argument for the implementation of early lung cancer screening programs, especially in communities with high levels of violent crime. Currently, lung cancer screening is often inaccessible and expensive, limiting its availability to those who need it most. This inequity exacerbates health disparities, as early detection is crucial for effective treatment and improved survival rates.

Are you or someone you know switching from cigarettes to vaping? 🚭🔄💨 Recent research presented at the ATS 2024 International Conference reveals a startling truth: ex-cigarette smokers who vape face a higher risk of lung cancer than those who don’t. In the largest study of its kind, researchers found that former smokers using e-cigarettes have a greater likelihood of developing and dying from lung cancer. The study evaluated over 4 million individuals, showing that e-cigarette users, regardless of how long they had quit smoking, faced increased risks compared to non-vapers. This groundbreaking research underscores the need for awareness. While vaping is often seen as a safer alternative, the potential harms cannot be ignored. E-cigarettes contain carcinogens like formaldehyde and toxic metals, similar to conventional cigarettes, posing significant health risks. Let’s rethink our approach to smoking cessation and consider the long-term consequences. Share this information, and let’s spread awareness about the potential dangers of vaping. #HealthRisk #LungCancer #Vaping #SmokingCessation #PublicHealth 🔗 Like, comment, and share to raise awareness! Image by Ethan Parsa

Aerion Bioscience BV Announces Groundbreaking Partnership with Rejuve.Bio to Transform Lung Cancer Screening We are proud to announce a strategic collaboration with Rejuve.Bio, a leading innovator in AI biotechnology. This partnership is set to revolutionize early lung cancer screening by integrating state-of-the-art AI with non-invasive diagnostic technologies. Together, we aim to significantly enhance early detection rates, offering new hope in the global battle against the leading cause of cancer-related deaths. In an era dominated by the urgent need for efficient and early cancer detection methods, Aerion Bioscience BV and Rejuve.Bio are committed to combining their expertise to confront this challenge. By leveraging Aerion's groundbreaking lung cancer screening platform and Rejuve.Bio's next-level AI and data analysis capabilities, this collaboration targets the development of a highly sensitive, non-invasive screening technology. This innovative approach aims to overcome the limitations of current screening methods, such as low-dose CT scans and blood tests, and to improve lung cancer companion diagnostics, identifying patients who would benefit most from specific treatments. Dr. Axel Schumacher, CEO of Aerion Bioscience BV, expressed his enthusiasm about the collaboration: "Uniting Aerion's biomarker panel with Rejuve Bio's pioneering neural-symbolic AI marks the beginning of a new era in lung cancer detection. Our joint endeavor is dedicated to redefining the standards for early detection and treatment, aiming to significantly improve patient outcomes." Echoing the excitement, Kennedy Schaal, CEO of Rejuve.Bio, highlighted the partnership's potential impact: "This collaboration leverages our AI biotechnology expertise with Aerion's innovative lung cancer screening technology. It's a significant step forward in our mission to extend human healthspan and save lives through early detection." The collaboration between Aerion Bioscience BV and Rejuve.Bio sets a new benchmark in the field of lung cancer screening, offering a cost-effective, non-invasive solution that reduces false positives and unnecessary medical interventions. Our joint efforts are not just about transforming cancer care; they symbolize a broader commitment to enhancing human healthspan, ensuring that early, accurate detection is accessible to all, and extending both the quality and duration of life. As part of our exciting journey, Aerion Bioscience BV is delighted to engage with the community and stakeholders. We invite you to follow our progress, engage with our stories, and join a movement dedicated to pioneering the future of global health in the fight against lung cancer. Together, we are not merely pursuing a breakthrough; we are setting the stage for a healthier future for millions around the globe. See here Rejuve.Bio's new crowdfunding campaign: https://lnkd.in/eFEng_zJ

Read our new blog post! Rejuve Bio Announces Strategic Collaboration with Aerion Bioscience BV to Revolutionize Lung Cancer Screening https://lnkd.in/gsKrK6Ny

We're honored to be supported by NLC Health Ventures as we embark on a transformative journey with Aerion Bioscience, a beacon of hope in the fight against lung cancer. Our innovative, non-invasive blood test represents a breakthrough in early detection, offering a lifeline to millions at high risk. With the leadership of Dr. Axel Schumacher and the support of NLC Health Ventures, we're not just envisioning a future where lung cancer can be detected early - we're actively creating it. This is an unparalleled opportunity for investors to join us in reshaping healthcare and saving lives. Together, we can turn the tide against lung cancer. #lungcancer #longevity #diagnostics #cancer

We're honored to be supported by NLC Health Ventures as we embark on a transformative journey with Aerion Bioscience, a beacon of hope in the fight against lung cancer. Our innovative, non-invasive blood test represents a breakthrough in early detection, offering a lifeline to millions at high risk. With the leadership of Dr. Axel Schumacher and the support of NLC Health Ventures, we're not just envisioning a future where lung cancer can be detected early - we're actively creating it. This is an unparalleled opportunity for investors to join us in reshaping healthcare and saving lives. Together, we can turn the tide against lung cancer. #lungcancer #longevity #diagnostics #cancer

Exciting developments at Aerion Bioscience, formed in collaboration with NLC Health Ventures, mark a pivotal moment in our mission to revolutionize early lung cancer detection. Lung cancer, the world's second most common (and most deadly) cancer, presents significant early detection challenges that have historically limited survival rates. Our innovative approach introduces a non-invasive blood test, utilizing a validated 6-protein biomarker panel, poised to dramatically improve outcomes for millions at high risk. Led by our CEO, Dr. Axel Schumacher Schumacher, Aerion is not merely filling existing gaps in screening methodologies but is on a path to fundamentally change the future of lung cancer detection and save countless lives. Join us on this transformative journey.